Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
wasabi.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series
Creator
Gori, Andrea
Bandera, Alessandra
Longhi, Benedetta
Alagna, Laura
Biffi, Stefano
Colombini, Antonella
Foresti, Sergio
Rizzari, Carmelo
Rovelli, Attilio
Verna, Marta
Gori, An-Drea
Migliorino, Guglielmo
Peri, Anna
topic
covid:5688f38645b50f19f5b36727b64e89bf73ad453c#this
Source
PMC
abstract
BACKGROUND: Invasive mold infections in children with hematological malignancies are associated with high mortality rates. The use of combination antifungal therapy in cases with a severe clinical course is increasing, although information on the efficacy and safety of this approach is limited. METHODS: We present a case series of 13 children affected by hemato-oncological disorders who received combination antifungal therapy for invasive mold infections at our center (Pediatric Hematology, San Gerardo Hospital, Monza, Italy) from 2011 to 2016, with the aim of describing their clinical characteristics, types of infections, treatment regimens, clinical outcomes, and treatment safety. Medical records were retrospectively reviewed in order to describe patients' characteristics. RESULTS: Combination antifungal therapy included liposomal amphotericin associated with caspofungin (5/13, 38.4%), voriconazole (5/13, 38.4%), or posaconazole (3/13, 23.1%). The 12-week treatment response rate was 69.2% (6/13 patients showed complete response, 3/13 partial response). The crude mortality was 30.7% (4/13): half was related to invasive mold infections (2/13, 15.38%) and half to disease progression (2/13, 15.38%). Overall, treatment was well tolerated, and we did not observe any permanent discontinuation of antifungals due to related side effects. CONCLUSIONS: In our experience, combination antifungal therapy seems to be a safe option in immunocompromised children with invasive mold infections. Well-designed studies are needed to confirm the safety of this approach and to better understand its efficacy in the pediatric setting.
has issue date
2019-09-05
(
xsd:dateTime
)
bibo:doi
10.20411/pai.v4i2.299
bibo:pmid
31538132
has license
cc-by
sha1sum (hex)
5688f38645b50f19f5b36727b64e89bf73ad453c
schema:url
https://doi.org/10.20411/pai.v4i2.299
resource representing a document's title
Combination Antifungal Therapy for Invasive Mold Infections Among Pediatric Patients with Hematological Malignancies: Data from A Real-Life Case-Series
has PubMed Central identifier
PMC6742350
has PubMed identifier
31538132
schema:publication
Pathog Immun
resource representing a document's body
covid:5688f38645b50f19f5b36727b64e89bf73ad453c#body_text
is
http://vocab.deri.ie/void#inDataset
of
proxy:http/ns.inria.fr/covid19/5688f38645b50f19f5b36727b64e89bf73ad453c
is
schema:about
of
named entity 'safety'
named entity 'Invasive'
named entity 'CASE'
named entity 'INVASIVE'
named entity 'MOLD'
named entity 'ANTIFUNGAL THERAPY'
named entity 'BACKGROUND'
named entity 'MORTALITY RATES'
named entity 'SERIES'
named entity 'PATIENTS'
named entity 'COMBINATION'
named entity 'INVASIVE'
named entity 'PEDIATRIC'
named entity 'HEMATOLOGICAL MALIGNANCIES'
named entity 'DATA'
named entity 'ANTIFUNGAL THERAPY'
named entity 'SEVERE CLINICAL COURSE'
named entity 'HEMATOLOGICAL MALIGNANCIES'
named entity 'USE OF'
named entity 'INFORMATION'
named entity 'INCREASING'
named entity 'LIMITED'
named entity 'APPROACH'
named entity 'INFECTIONS'
named entity 'COMBINATION'
named entity 'INFECTIONS'
named entity 'ASSOCIATED WITH'
named entity 'MOLD'
named entity 'SAFETY'
named entity 'EFFICACY'
named entity 'LIFE'
named entity 'REAL'
named entity 'CHILDREN'
named entity 'CASES'
named entity 'HIGH'
covid:arg/5688f38645b50f19f5b36727b64e89bf73ad453c
named entity 'Pediatric Patients'
named entity 'hematological malignancies'
named entity 'AKI'
named entity 'demographic characteristics'
named entity 'clinical setting'
named entity 'case series'
named entity 'fluconazole'
named entity 'malignancy'
named entity 'fusariosis'
named entity 'first-line'
named entity 'blood cultures'
named entity 'first-line'
named entity 'antifungal treatment'
named entity 'toxicity'
named entity 'GGT'
named entity 'combination therapy'
named entity 'salvage therapy'
named entity '7/10'
named entity 'morbidity'
named entity 'CNS'
named entity 'combination therapy'
named entity 'prophylaxis'
named entity 'hemato'
named entity 'CNS'
named entity 'non-Hodgkin lymphoma'
named entity 'hypokalemia'
named entity 'Hematology'
named entity 'immunocompromised'
named entity 'prophylaxis'
named entity 'antifungal'
named entity 'steroids'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 5
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software